Stocks · Health care · Pharmaceutical Preparations

Contineum Therapeutics, Inc.

CTNM Clue Score32
United States Fiscal year ends December CIK 0001855175 Results filed 3 Nov 2026

What the insiders did Scheduled selling only

By person

5 insiders · 35 transactions
0.4×

Carmine N. Stengone holds only 0.4 times base salary in stock. $283.33K of shares against $655.62K in salary for 2025.

Salary from the company's own proxy. The shares are what Carmine N. Stengone last reported holding, valued at $16.46, the price Class A Common Stock was last bought or sold at on the open market here, on 8 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Daniel S. Lorrain
Chief Scientific Officer
—
$1.25M (22) scheduled
−$1.25M
135,202
0.5853%
$2.22M
−23.1%
Carmine N. Stengone
CEO and President
—
$401.38K (7) scheduled
−$401.38K
17,217
0.0745%
$283.33K
0.0%
Tim Watkins
CMO & Head of Development
—
$322.56K (5) scheduled
−$322.56K
8,961
0.0388%
$147.47K
0.0%
Versant Venture Capital VI, L.P. entity
10% owner
—
—
—
148,312
0.6421%
$2.44M
—
Stephen L. Huhn
CMO & Sr VP, Clinical Dev.
—
—
—
12,800
0.0554%
$210.64K
—